BOSTON & OSAKA, Japan, June 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license ...

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet cell therapy appears to be paying off so far. The allogeneic human ...

About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex Pharmaceuticals announced the simultaneous presentation and publication of ...

Vertex Pharma's stem cell therapy may have potential to cure type-1 diabetes, shows clinical trial During a clinical trial, around 83% (10 out of 12) of patients who received a full dose of ...

See the latest Vertex Pharmaceuticals Inc stock price (VRTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Vertex could be closing in on a deal with the NHS over its portfolio of cystic fibrosis drugs, after health ministers wrote to the US firm asking for a conclusion to talks after almost two years ...

Sales of the ground-breaking cystic fibrosis (CF) drug Kaftrio was the main driver behind revenues of a Dublin unit of Vertex Pharmaceuticals surging to $2.63bn (€2.26bn) last year.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880.

A high-level overview of Vertex Pharmaceuticals Incorporated (VRTX) stock. View (VRTX) real-time stock price, chart, news, analysis, analyst reviews and more.

Janus Henderson Investors, an investment management company, released its “Janus Henderson Venture Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.